

Our Vision

To accelerate the development of next-generation biotherapeutics

Our Mission

Bridging the gap from target to lead

ANTIBODIES DEVELOPED IN GERMANY

YUMAB GmbH

YUMAB



Inhoffenstraße 7
38124 Braunschweig - Germany



info@yumab.com



+49 531 481170-0



www.yumab.com

Company

YUMAB develops therapeutic antibodies for clients and partners using one of world's largest human antibody libraries (>10e11), patient derived libraries or immune libraries. YUMAB's integrated discovery and engineering platform offers highest success-rates to all types of antigens including "difficult" targets such as GPCRs, transporters or ion channels. YUMAB provides all technologies from target to optimized lead in one hand. Technologies include fast track in vitro antibody selection and screening (including on cell selection), antibody engineering (including super-humanization) and bioinformatic lead optimization.



Products and technologies

- Fast track discovery of fully human antibodies
- Immune or patient derived libraries (also from transgenic animals)
- Antibody lead development (IgG, Fab, scFv, bispecifics, CAR, ADC, ...)
- Antibody engineering (affinity, stability, manufacturability)
- In silico lead optimization
- Hybridoma sequencing
- Humanization, Super-Humanization
- Contract research and development
- Partnered development

Strengths

- One of world's largest human antibody libraries
- (>10e11).
- Tailormade Antibodies.
- Collaborative approach.
- Modular Business Model/Terms.

Target clients

Biotech startups to large biopharma:

Potent partners from academia, clinics and industry allowing to access a broader expertise and technology portfolio for the mutual benefit of all partners. Focal points are novel technologies or novel indications and immunotherapeutic strategies. Our concept is to bring the best technologies and ideas together and to push the boundaries of current drug development to a new level.